Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Veloxis Pharmaceuticals A/S    VELO   DK0060048148

VELOXIS PHARMACEUTICALS A/S (VELO)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
0.915(c) 0.918(c) 0.92(c) 0.927(c) 0.939 Last
234 820 82 180 107 101 105 821 213 860 Volume
-1.51% +0.33% +0.22% +0.76% +1.29% Change
More quotes
Financials (DKK)
Sales 2018 122 M
EBIT 2018 76,5 M
Net income 2018 71,4 M
Debt 2018 10,2 M
Yield 2018 -
Sales 2019 174 M
EBIT 2019 111 M
Net income 2019 105 M
Finance 2019 77,9 M
Yield 2019 -
P/E ratio 2018 47,18
P/E ratio 2019 18,40
EV / Sales2018 13,0x
EV / Sales2019 8,61x
Capitalization 1 574 M
More Financials
Company
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients.The company is focused on the direct commercialization of Envarsus XR in the US,... 
More about the company
Surperformance© ratings of Veloxis Pharmaceuticals A/
Trading Rating : Investor Rating :
More Ratings
Latest news on VELOXIS PHARMACEUTICALS A/
06/04VELOXIS PHARMACEUTICALS A/S : Partners with the American Society of Transplant S..
AQ
05/18VELOXIS PHARMACEUTICALS A/S : Announces Financial Results for the First Three Mo..
AQ
05/16CORRECTION : Veloxis Pharmaceuticals Announces Financial Results for the First T..
PU
05/14VELOXIS PHARMACEUTICALS A/S : Announces Financial Results for the First Three Mo..
AQ
05/09VELOXIS PHARMACEUTICALS A/S : quaterly earnings release
04/26VELOXIS PHARMACEUTICALS A/S : FDA Accepts Veloxis's Supplemental New Drug Applic..
AQ
04/20VELOXIS PHARMACEUTICALS A/S : Grants Warrants under Existing Warrant Program
AQ
04/20VELOXIS PHARMACEUTICALS A/S : FDA Accepts Veloxis's Supplemental New Drug Applic..
PU
04/19VELOXIS PHARMACEUTICALS A/S : FDA Accepts Veloxis’s Supplemental New Drug ..
AQ
04/18VELOXIS PHARMACEUTICALS A/S : Grants Warrants Under Existing Warrant Program
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/17/C O R R E C T I O N -- Veloxis Pharmaceuticals/  
05/16Correction: Veloxis Pharmaceuticals Announces Financial Results for the First.. 
05/15Veloxis Pharmaceuticals Announces Financial Results for the First Three Month.. 
05/15Veloxis Pharmaceuticals : Announces Financial Results for the First Three Mon.. 
04/20FDA Accepts Veloxis’s Supplemental New Drug Application for Envarsus XR: Velo.. 
More tweets
Qtime:51
News from SeekingAlpha
05/15Veloxis Pharmaceuticals  reports Q1 results 
2016Veloxis Pharmaceuticals reports 1H16 results 
2015Veloxis Pharma's once-daily Envarsus an Orphan Drug for prevention of organ r.. 
2015PREMARKET BIOTECH DIGEST : Pfizer In China, Anavex Alzheimer's Focus 
2015FDA clears Veloxis Pharma's extended-release Envarus for the prevention of re.. 
Chart VELOXIS PHARMACEUTICALS A/
Duration : Period :
Veloxis Pharmaceuticals A/ Technical Analysis Chart | VELO | DK0060048148 | 4-Traders
Technical analysis trends VELOXIS PHARMACEUTICALS A/
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 0,94  DKK
Spread / Average Target 2,2%
EPS Revisions
Managers
NameTitle
Craig A. Collard President & Chief Executive Officer
Michael Thomas Heffernan Chairman
Morten Marott Chief Financial Officer
Ulf Meier-Kriesche Chief Scientific Officer
Anders Götzsche Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VELOXIS PHARMACEUTICALS A/S6.98%244
CELLTRION, INC.--.--%33 593
IQVIA HOLDINGS INC7.88%21 859
LONZA GROUP2.81%19 855
INCYTE CORPORATION-22.94%15 470
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 517